開發包覆靛氰綠和喜樹鹼之複合水凝膠用於黑色素瘤光/化學治療之研究

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：19

、訪客IP：18.118.37.224

姓名

鍾杰霖(Chieh-Lin Chung) 查詢紙本館藏

畢業系所

生物醫學工程研究所

論文名稱

開發包覆靛氰綠和喜樹鹼之複合水凝膠用於黑色素瘤光/化學治療之研究
(Development of Indocyanine Green and Camptothecin loaded Hyaluronic Acid Hydrogel For Photochemotherapy of Skin Cancer)

相關論文

★ 可動態改變外翻力矩的治療退化性膝關節炎輔具	★ 聚乙二醇對於擬球藻生長與脂質堆積之影響
★ 製備包覆靛氰綠及阿黴素之聚乳酸甘醇酸-聚乙二醇交聯標靶奈米粒子用於乳癌光/化學治療之研究	★ 研製包覆靛氰綠與阿黴素之標靶氟化奈米乳劑用於乳癌光/化學治療之研究
★ 研究設計全氟碳化物光生物反應器系統用以純化沼氣並藉此提升微藻生物質及生質能源之產量	★ 針對糖尿病足潰瘍設計並製作一種抗菌且能促進傷口癒合的甲殼素複合式水凝膠之研究
★ 利用PLGA微球載體結合超聲波駐波場以提高巨噬細胞藥物輸送之效率	★ 以血流動力系統探討血管內皮細胞在尼古丁刺激下對層流剪應力之型態異常與自體凋亡之表現變化
★ 以板式流道系統模擬血管內皮細胞於層流剪力影響下受尼古丁刺激產生發炎反應之研究	★ 結合超聲波駐波場與層堆疊自體組裝微球載體建構提高分子傳遞至細胞內效率之方法
★ 製備包覆靛氰綠之聚乳酸甘醇酸標靶奈米粒子用於乳癌光熱暨光動治療之研究	★ 建構駐波聲場光生物反應器系統用於提升密閉式微藻養殖效能之研究
★ 研製包覆靛氰綠與利福平之聚乳酸-聚甘醇酸奈米粒子應用於介質內細菌感染治療之研究	★ 雙離子矽氧烷共聚物以沉積法對聚二甲基矽氧烷進行生物相容性修飾
★ 開發具有抗菌、消炎、供氧及促使細胞生長特性可注射溫感性水凝膠用於慢性傷口癒合之研究	★ 設計開發一多效複合式殼聚醣水凝膠用於慢性傷口修復之研究

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

至系統瀏覽論文 ( 永不開放)

摘要(中)

皮膚癌是最常見的癌症之一，它主要由太陽紫外線輻射所引起。在各種皮膚癌中，黑色素瘤最為致命，約佔皮膚癌的10%。當黑色素細胞在紫外線輻射下迅速複製和變異時，就會形成黑色素瘤。雖然黑色素瘤的發病率很低，但它具有轉移能力、難以治愈且具有致命性。根據以往的研究，早期的黑色素瘤主要治療方法為手術治療，然而在治療過後仍有殘留的情況發生。為了解決這個問題，我們開發了包覆靛菁綠(ICG)和喜樹鹼(CPT)的複合水凝膠（Indocyanine Green and Camptothecin loaded Hyaluronic Acid Hydrogel；ICHHG），希望將光治療與化學治療相結合，通過兩種不同的治療方式減少化療藥物的用量，從而降低化學治療所引起的副作用。此外，該材料能夠長時間附著於皮膚表面並控制藥物的釋放，成功克服了傳統皮膚給藥方式的局限性。

摘要(英)

Skin cancer is one of the most common types of cancer, primarily caused by ultraviolet (UV) radiation from the sun. Among various types of skin cancer, melanoma is the most lethal, accounting for approximately 10% of skin cancer cases. Melanoma develops when melanocytes rapidly replicate and mutate under UV radiation. Although the incidence rate of melanoma is relatively low, it is highly metastatic, difficult to cure, and potentially fatal. According to previous studies, early-stage melanoma is primarily treated through surgical excision; however, residual cancer cells may persist after treatment. To address this issue, we developed a composite hydrogel encapsulating indocyanine green (ICG) and camptothecin (CPT) (Indocyanine Green and Camptothecin loaded Hyaluronic Acid Hydrogel; ICHHG). This hydrogel aims to combine phototherapy and chemotherapy, reducing the required dosage of chemotherapeutic drugs through dual therapeutic approaches, thereby minimizing the side effects associated with chemotherapy. Additionally, the material can adhere to the skin surface for an extended period and control drug release, effectively overcoming the limitations of traditional skin drug delivery methods.

關鍵字(中)

★ 黑色素瘤
★ 靛青綠
★ 喜樹鹼
★ 透明質酸
★ 水凝膠
★ 光化學治療

關鍵字(英)

★ Melanoma
★ Indocyanine green
★ Hippocampus
★ Hyaluronic acid
★ Hydrogel
★ Photochemotherapy

論文目次

摘　要 i
Abstract ii
致　謝 iii
目　錄 iv
圖　目　錄 vii
縮　寫　符　號　說　明 x
第一章緒論 1
1-1 研究背景 1
1-2 研究目的 3
第二章文獻探討 4
2-1 皮膚癌(Skin cancer) 4
2-1-1 皮膚癌分類 4
2-1-2 黑色素瘤分期 6
2-1-3 黑色素瘤致病因素 7
2-1-4 黑色素瘤治療方式 8
2-2 光治療 9
2-2-1 光敏劑 10
2-2-2 光熱治療 10
2-3 水凝膠 11
2-3-1 水凝膠 11
2-3-2 溫感性水凝膠 11
2-4 藥品 13
2-4-1 靛氰綠（Indocyanine green, ICG） 13
2-4-2 喜樹鹼（Camptothecin, CPT） 14
2-4-3 泊洛沙姆(Pluronic F127, PEO-PPO-PEO） 15
2-4-4 透明質酸(Hyaluronic acid, HA） 15
第三章實驗器材與方法 17
3-1 實驗藥品及儀器設備 17
3-1-1 實驗藥品 17
3-1-2 儀器設備 19
3-2 實驗流程表 21
3-3 六亞甲基二異氰酸(HDI)接枝的泊洛姆高分子之製備 22
3-4 製備包覆ICG、CPT之水凝膠(ICHHG) 22
3-5 ICHHG之基礎物理性質測定 24
3-5-1 核磁共振光譜(1H-NMR)分析HDI-PF127高分子 24
3-5-2 超高解析冷場發射掃描式電子顯微鏡拍攝(FE-SEM) 24
3-5-3 熱重分析(TGA) 25
3-5-4 流變儀 25
3-5-5 Free ICG & ICHHG光敏劑穩定性測定 26
3-5-6 ICHHG藥物釋放率測定 27
3-6 光療效果試驗 28
3-6-1 Free ICG & ICHHG光熱效果測定 28
3-7 體外試驗 29
3-7-1 體外細胞毒性試驗 29
3-8 統計與分析 31
第四章實驗結果與討論 32
4-1 ICHHG之基礎物理性質 32
4-1-1 ICHHG之外觀 32
4-1-2 核磁共振光譜(1H-NMR)分析HDI-PF127高分子 33
4-1-3 ICHHG之表面形態分析 34
4-1-4 TGA熱重分析 34
4-1-5 流變儀 35
4-1-6 Free ICG & ICHHG光敏劑穩定性測定 36
4-1-7 ICHHG抗癌藥物釋放率測定 37
4-1-8 ICHHG照光後藥物釋放 38
4-2 ICHHG之光療效果試驗 40
4-2-1 Free ICG & ICHHG光熱升溫效果測試 40
4-3 體外試驗 41
4-3-1 Free ICG & Free CPT & ICHHG之體外細胞毒性試驗 41
第五章結果與未來展望 44
參考文獻 45

參考文獻

[1] Ferlay, Jacques, et al. "Cancer statistics for the year 2020: An
[2] Arnold, Melina, et al. "Global burden of cutaneous melanoma in 2020 and projections to 2040." JAMA dermatology 158.5 (2022): 495-503.
[3] World Health Organization : <Global burden of cutaneous melanoma in 2020 and projections to 2040>, https://www.iarc.who.int/infographics/global-burden-of-cutaneous-melanoma-in-2020-and-projections-to-2040/
[4] 出境醫：<黑色素瘤治療，美國日本治療黑色素瘤>, https://zhiliao.chujingyi.cn/hssl
[5] Linares, Miguel A., Alan Zakaria, and Parminder Nizran. "Skin cancer." Primary care: Clinics in office practice 42.4 (2015): 645-659.
[6] National Cancer Institute : <Skin Cancer, Basal Cell Carcinoma, Superficial>, https://visualsonline.cancer.gov/details.cfm?imageid=9236
[7] Habif, Thomas P., and J. L. Campbell. "Premalignant and malignant nonmelanoma skin tumors." Clinical dermatology 4 (2004): 744-7.
[8] National Cancer Institute : <Squamous Cell Carcinoma>, https://visualsonline.cancer.gov/details.cfm?imageid=2165
[9] Rinker, Margaret H., et al. "Histologic variants of squamous cell carcinoma of the skin." Cancer Control 8.4 (2001): 354-363.
[10] Schadendorf, Dirk, et al. "Melanoma." The Lancet 392.10151 (2018): 971-984.
[11] National Cancer Institute: <Melanoma>, https://visualsonline.cancer.gov/details.cfm?imageid=9188
[12] Rathi, Vikas K., et al. "Cardiovascular magnetic resonance of the charcoal heart." Journal of Cardiovascular Magnetic Resonance 10.1 (2008): 1-4.
[13] Tsatsou, Fragkiski, et al. "Extrinsic aging: UV-mediated skin carcinogenesis." Dermato-endocrinology 4.3 (2012): 285-297.
[14] Bristow, Ivan R., and Katharine Acland. "Acral lentiginous melanoma of the foot and ankle: a case series and review of the literature." Journal of Foot and Ankle Research 1.1 (2008): 1-5.
[15] Keung, Emily Z., and Jeffrey E. Gershenwald. "The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care." Expert review of anticancer therapy 18.8 (2018): 775-784.
[16] Scientific Animations：<Melanoma skin cancer: Symptoms, Causes, & Treatment>, https://www.scientificanimations.com/3d-medical-animation-melanoma-skin-cancer-symptoms-causes-treatment/uncategorized/
[17] Schadendorf, Dirk, et al. "Melanoma." The Lancet 392.10151 (2018): 971-984.
[18] Miller, Arlo J., and Martin C. Mihm Jr. "Melanoma." New England Journal of Medicine 355.1 (2006): 51-65.
[19] Schadendorf, Dirk, et al. "Melanoma." Nature reviews Disease primers 1.1 (2015): 1-20.
[20] Moustafa, Danna, Andrew R. Blundell, and Elena B. Hawryluk. "Congenital melanocytic nevi." Current Opinion in Pediatrics 32.4 (2020): 491-497.
[21] Elder, David E., et al. "Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma." Cancer 46.8 (1980): 1787-1794.
[22] Guo, Weinan, Huina Wang, and Chunying Li. "Signal pathways of melanoma and targeted therapy." Signal Transduction and Targeted Therapy 6.1 (2021): 424.
[23] Rose, D. Michael, et al. "Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience." Archives of surgery 136.8 (2001): 950-955.
[24] Ollila, David W., et al. "Surgical resection for melanoma metastatic to the gastrointestinal tract." Archives of surgery 131.9 (1996): 975-980.
[25] Wilson, Melissa A., and Lynn M. Schuchter. "Chemotherapy for melanoma." Melanoma (2016): 209-229.
[26] Lee, Siow Ming, Daniel C. Betticher, and Nick Thatcher. "Melanoma: chemotherapy." British medical bulletin 51.3 (1995): 609-630.
[27] Bajetta, Emilio, et al. "Metastatic melanoma: chemotherapy." Seminars in oncology. Vol. 29. No. 5. WB Saunders, 2002.
[28] Yang, Arvin S., and Paul B. Chapman. "The history and future of chemotherapy for melanoma." Hematology/Oncology Clinics 23.3 (2009): 583-597.
[29] Finger, Paul T. "Radiation therapy for choroidal melanoma." Survey of ophthalmology 42.3 (1997): 215-232.
[30] Mahadevan, Anand, Vivek L. Patel, and Nergiz Dagoglu. "Radiation therapy in the management of malignant melanoma." Oncology 29.10 (2015): 743-743.
[31] Wong, Deborah JL, and Antoni Ribas. "Targeted therapy for melanoma." Melanoma (2016): 251-262.
[32] Czarnecka, Anna M., et al. "Targeted therapy in melanoma and mechanisms of resistance." International journal of molecular sciences 21.13 (2020): 4576.
[33] Gray-Schopfer, Vanessa, Claudia Wellbrock, and Richard Marais. "Melanoma biology and new targeted therapy." Nature 445.7130 (2007): 851-857.
[34] Sanlorenzo, Martina, et al. "Melanoma immunotherapy." Cancer biology & therapy 15.6 (2014): 665-674.
[35] Kirkwood, John M., et al. "Next generation of immunotherapy for melanoma." Journal of Clinical Oncology 26.20 (2008): 3445-3455.
[36] Lugowska, Iwona, Pawel Teterycz, and Piotr Rutkowski. "Immunotherapy of melanoma." Contemporary Oncology/Wspo?czesna Onkologia 2018.1 (2018): 61-67.
[37] Weiss, Sarah A., Jedd D. Wolchok, and Mario Sznol. "Immunotherapy of Melanoma: Facts and HopesImmunotherapy of Melanoma." Clinical Cancer Research 25.17 (2019): 5191-5201.
[38] Shi, Huayun, and Peter J. Sadler. "How promising is phototherapy for cancer?." British Journal of Cancer 123.6 (2020): 871-873.
[39] Vreman, Hendrik J., Ronald J. Wong, and David K. Stevenson. "Phototherapy: current methods and future directions." Seminars in perinatology. Vol. 28. No. 5. WB Saunders, 2004.
[40] Bown, S. G. "Phototherapy of tumors." World journal of surgery 7 (1983): 700-709.
[41] Honigsmann, Herbert. "History of phototherapy in dermatology." Photochemical & photobiological sciences 12 (2012): 16-21.
[42] Allison, Ron R., et al. "Photosensitizers in clinical PDT." Photodiagnosis and photodynamic therapy 1.1 (2004): 27-42.
[43] Agostinis, Patrizia, et al. "Photodynamic therapy of cancer: an update." CA: a cancer journal for clinicians 61.4 (2011): 250-281.
[44] Dolmans, Dennis EJGJ, Dai Fukumura, and Rakesh K. Jain. "Photodynamic therapy for cancer." Nature reviews cancer 3.5 (2003): 380-387.
[45] Han, Hwa Seung, and Ki Young Choi. "Advances in nanomaterial-mediated photothermal cancer therapies: toward clinical applications." Biomedicines 9.3 (2021): 305.
[46] Zou, Lili, et al. "Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics." Theranostics 6.6 (2016): 762.
[47] Zhi, Defu, et al. "Photothermal therapy." Journal of Controlled Release 325 (2020): 52-71.
[48] Lin, Ying-Yi, et al. "Cell-derived artificial nanovesicle as a drug delivery system for malignant melanoma treatment." Biomedicine & Pharmacotherapy 147 (2022): 112586.
[49] M.S.(2020).NMR relaxation and self-diffusion in aqueous micellar gels of pluronic F127.Journal of Molecular Liquids,306(2020) ,2.https://doi.org/10.1016/j.molliq.2020.112898
[50] Lotvall, Jan, et al. "Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles." Journal of extracellular vesicles 3.1 (2014): 26913.
[51] Thery, Clotilde, et al. "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines." Journal of extracellular vesicles 7.1 (2018): 1535750.
[52] Kim, Kimin, et al. "Cyclic tangential flow filtration system for isolation of extracellular vesicles." APL bioengineering 5.1 (2021): 016103.
[53] Tkach, Mercedes, and Clotilde Thery. "Communication by extracellular vesicles: where we are and where we need to go." Cell 164.6 (2016): 1226-1232.
[54] Raposo, Graca, and Philip D. Stahl. "Extracellular vesicles: a new communication paradigm?." Nature Reviews Molecular Cell Biology 20.9 (2019): 509-510.
[55] Sheng, Danli, et al. "Perfluorooctyl bromide & indocyanine green co-loaded nanoliposomes for enhanced multimodal imaging-guided phototherapy." Biomaterials 165 (2018): 1-13.
[56] Reinhart, Michaela B., et al. "Indocyanine green: historical context, current applications, and future considerations." Surgical innovation 23.2 (2016): 166-175.
[57] Tovar, Johan Sebastian Diaz, et al. "Photodegradation in the infrared region of indocyanine green in aqueous solution." 2019 SBFoton International Optics and Photonics Conference (SBFoton IOPC). IEEE, 2019.
[58] Norris Pharm : <DS-8201不是終點：喜樹鹼和ADC的開發以及增強治療效果的策略>,http://www.norris-pharm.com/en/NewsView/35868d4c-af65-4605-9013-628608d4a7bc
[59] Thomas, Craig J., Nicolas J. Rahier, and Sidney M. Hecht. "Camptothecin: current perspectives." Bioorganic & medicinal chemistry 12.7 (2004): 1585-1604.
[60] Kumari, Anshu, and Sharad Gupta. "Two?photon excitation and direct emission from S2 state of US Food and Drug Administration approved near?infrared dye: Application of anti?Kasha′s rule for two?photon fluorescence imaging." Journal of Biophotonics 12.1 (2019): e201800086.
[61] Riess, Jean G. "Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery." Artificial cells, blood substitutes, and biotechnology 33.1 (2005): 47-63.
[62] Jagers, Johannes, Anna Wrobeln, and Katja B. Ferenz. "Perfluorocarbon-based oxygen carriers: from physics to physiology." Pflugers Archiv-European Journal of Physiology 473 (2021): 139-150.

指導教授

李宇翔(Yu-Hsiang Lee)

審核日期

2025-1-22

推文